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It’s Time
2
Open the window of 
your mind.
Throw out the trash
Let in fresh  air and 
ideas
Extracts from Helsinki Protocol - 1
3
The World Medical Association (WMA) has developed the Declaration of 
Helsinki as a statement of ethical principles for medical research involving 
human subjects, including research on identifiable human material and data. 
The Declaration of Geneva of the WMA binds the physician with the words, “The 
health of my patient will be my first consideration.” 
International Code of Medical Ethics declares that, “A physician shall act in the 
patient's best interest when providing medical care.”
Physicians must immediately stop a study when the risks are found to outweigh 
the potential benefits or when there is conclusive proof of positive and 
beneficial results.
Extracts from Helsinki Protocol- 2
In the treatment of a patient, where proven interventions do
not exist or have been ineffective, the physician, after seeking expert 
advice, with informed consent from the patient or a legally 
authorized representative, may use an unproven intervention if in 
the physician's judgement it offers hope of saving life, re-establishing 
health or alleviating suffering. Where possible, this intervention 
should be made the object of research, designed to evaluate its 
safety and efficacy. 
In all cases, new information should be recorded and, where 
appropriate, made publicly available.
THIS IS THE PURPOSE OF THIS LECTURE
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What is Carnitine Transporter
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Needed for transfer of long‐chain fatty acids across the inner mitochondrial 
membrane for its utilisation/ oxidation.
Requires enzymes and transporters that accumulate carnitine within the cell 
(OCTN2: carnitine transporter), conjugate it with long chain fatty acids (CPT1: 
carnitine palmitoyl transferase 1), transfer the acylcarnitine across the inner 
plasma membrane (CACT: carnitine ‐acylcarnitine translocase), and conjugate the 
fatty acid back to Coenzyme A for subsequent beta oxidation (CPT2: carnitine 
palmitoyl transferase 2). 
◦ Primary Carnitine Deficiency and Cardiomyopathy, 
Lijun Fu et al, http://dx.doi.org/10.4070/kcj.2013.43.12.785 
◦ Disorders of carnitine transport and the carnitine cycle, Nicola Longo et al, Am J Med Genet C 





Deficiency result of Carnitine Transporter
Deficiency of the OCTN2 carnitine transporter causes primary 
carnitine deficiency, characterized by increased losses of carnitine in 
the urine & decreased carnitine accumulation in tissues. 
Possible Presentations: 
1. Skeletal and CARDIAC MYOPATHY 
2. Hypoketotic hypoglycemia and hepatic encephalopathy
6
Management that usually 
but NOT always, works
7
Treatment for carnitine consists in a low‐fat diet 
supplemented with medium chain triglycerides that 
can be metabolized by mitochondria independently 
from carnitine, (mega-dose) Carnitine supplements, 
& avoidance of fasting and sustained exercise.
◦Mitochondrial Cardiomyopathy, Deborah E. Meyers et al, 
Texas Heart Inst J. 2013; 40(4): 385–394
Carnitine Transporter Deficiency 
Cardiomyopathy
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Carnitine Transporter Deficiency induced cardiomyopathy is a rare 
autosomal recessive genetic disorder, characterized by plasma 
membrane carnitine transport defect, impairing uptake and 
oxidation of long chain fatty acids at the mitochondrial level
◦ A. Cano et al, Ped. Cardiol. 2008; 29(1): 163-165
This may cause oedema, sometimes therapy resistant heart failure, 
metabolic acidosis, hypoglycaemia, muscle weakness. 
Investigations show normal PFT, ECG with giant T waves with 
prolonged QT intervals, subnormal blood carnitine levels and highly 
abnormal Echo Cardiogram
The case of QAB: severe carnitine 
transporter deficiency cardiomyopathy
9
QAB was diagnosed at Aga Khan University (AKU) Hospital, Karachi, as a 
progressive case of Congenital Cardiomyopathy in childhood due to of Carnitine 
Transporter Deficiency. 
Family History: 2 pre-teen brothers earlier succumbed to this disease. One sister 
and one brother seem to have been spared. QAB affected. He had been on heart 
failure medications and mega dose L-carnitine as per prevailing medical practice, 
which had helped to prolong his life till 16 years with relapse and remissions. He 
exhibited slowly deteriorating heart failure, in spite of optimum recommended 
carnitine supplementation plus heart failure therapy. 
Presented in Jan.  2015 with LVEF 20-25% as recorded at AKU, Fortis C-DOC 


















COA of MSC 
used
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Treatment given to QAB by us
Mega dose L-Carnitine + CHF therapies continued as at AKU Hosp. 
(Dr. M Atiq) plus salt restricted non-strainous life style.
HBOT 1.5 ATA with 100% Oxygen, 15 minutes to dive plus 15 minutes 
to surface plus 60 minutes at full pressure x 40 sessions. After 20 
sessions, we proceeded to transplant Stem Cell.
◦ OUR HYPOTHESIS: The heart is merely starving and is showing secondary 
effects of this. Carnitine Transporters are proteins, majority synthesized in the 
LIVER. Why not help the liver also?
◦ Hence, we gave 1/3rd  dose of fresh MSC calculated/kg body weight,
in Coronary arteries to help the weakened heart & the rest 2/3rd  in the liver 






Table 1: LVEF data from Echo-Cardiogram record.
Date: Y/M/D Where Done LVEF %
2006/01/13 AK Univ. Hosp. Karachi 30
2006/12/29 AK Univ. Hosp. Karachi 59
2007/02/26 AK Univ. Hosp. Karachi 60
2007/06/04 AK Univ. Hosp. Karachi 60
2008/01/14 AK Univ. Hosp. Karachi 58
2008/05/05 AK Univ. Hosp. Karachi 34
2008/08/04 AK Univ. Hosp. Karachi 47 Dx done
2009/05/20 AK Univ. Hosp. Karachi 50
2009/10/14 AK Univ. Hosp. Karachi 54
2010/05/26 AK Univ. Hosp. Karachi 55
2010/12/31 AK Univ. Hosp. Karachi 70
2011/02/09 AK Univ. Hosp. Karachi 56
2011/08/22 AK Univ. Hosp. Karachi 50
2012/02/20 AK Univ. Hosp. Karachi 55
2013/01/02 AK Univ. Hosp. Karachi 30
2013/04/03 AK Univ. Hosp. Karachi 32
2013/04/15 AK Univ. Hosp. Karachi 26
2014/10/22 AK Univ. Hosp. Karachi 30
2015, January Initial at Fortis C-DOC Hospital, Delhi 20   1st Procedure
2015/02/31 After HBOT+SCT, Natl.Heart Inst,Delhi 35   Post-Proc.
2015 July AK Univ. Hosp. Karachi 55
2016 January Post Procedure, NHI, Delhi 55   2nd Procedure
2017 January AK Univ. Hosp. Karachi 84   Stable
2018, January AK Univ. Hosp. Karachi 55   Neglecting Rx still LVEF Ok
Stem Cell delivery to QA
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Heart & Liver as shown
HEART LIVER
Outcome of therapy (Jan 2015 )
LVEF went up from 20% to 35% (Fortis C-Doc Hospital, Delhi: immediate HBOT action) within 6 
weeks, by February 2015
LVEF went up to 55% (delayed SCT Effect) by Mid 2015.
January 2016, LVEF maintained at 55%. (Normal)
1st Booster dose of HBOT + SCT given as before.
January 2017, LVEF reached 80 – 85% (Maximum normal)
Boy felt so good, he became like any naughty boy of his age, indulged in by his father who had 
already lost two sons to the disease. 
He neglected regular medications, diet control & life style guidelines to a fair degree.
January 2018, LVEF still at 55%, doing well and enjoying normal life.
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Discussion 1
This being a treatment failure case of carnitine transporter deficiency induced 
cardiomyopathy, who appeared to be in the last lap of his lifespan, we decided to use 
desperate measures under the provisions of Helinki Protocol Para 35.
Carnitine is a naturally occurring hydrophilic amino acid derivative, produced endogenously in 
the kidneys and liver and derived from meat and dairy products in the diet.
Cannot easily enter mitochondria and get oxidized for energy production and formation of 
ketones for brain function. 
◦ Fernando Scaglia (2014) Carnitine Deficiency
Carnitine plays an essential role in the transfer of long chain fatty acids into the mitochondria for 
beta-oxidation.
◦ Longa N, Amat C, Pasquali M (2003) The OVTN2 carnitine transporter and fatty acid oxidation. 
Membrane transporter disease, pp. 161-174.
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Discussion 2
We chose to use HBOT, prior to use of stem cell therapy 
based on the work of Diaj-Barbosa et al. in early 2000s. 
They showed that stem cell therapy in the middle of HBOT, 
gave a greater benefit than either therapy alone. 
◦ JL Diaz-Barbosa & FJ Morales; (July 2003) 3rd Int. Symposium on Cerebral Palsy and the Brain Injured 
Child. Fort Lauderdale, Florida.
◦ JJ Catherine, Tonseth KA, Utheim TP (2017) Cultured epidermal stem cell in regenerative medicine. Stem 
Cell Res Ther 8(15): 155.
We followed similar protocol with on-site transplantation
19
Conclusion: 
Carnitine Transporter Deficiency Cardiomyopathy
No adverse reaction from our treatment protocol, even after 3 years. 
It is difficult to quantify the relative degree of help obtained by this 
previously non-responder case, from HBOT, stem cell therapy and 
both given together. 
Not enough cases per center to do a DBPCR Trial. Hence, going by this 
single safe and effective case study record, we propose to follow the 
same protocol for future cases if any, till we have more data.




A NEW APPROACH IN MEDICINE 
using HBOT + Stem Cells.
We have many more cards up our 
sleeve, but that is for the next time
Our Philosophy in NDD is to use:
LIFE STYLE MANAGEMENT
Multimode approach regulated by INDIVIDUAL NEED only.
◦ Comprehensive individual need based Standard Therapies: COMPULSARY
◦ Biomedical need-based approach, using special diets + micronutrients, with regular follow up 
adjustments as per age, sex, weight, need, etc. + drugs:
IF NEEDED
◦ HBOT, based on SPECT 3D Fusion Scan: IF NEEDED
◦ rTMS with NFB , based on SPECT 3D Fusion Scan: IF NEEDED
◦ Sensory Integration Therapy, based on Clinical Findings: IF NEEDED
◦ Ayurveda / Unani based brain repairing agents and antivirals: IF NEEDED
◦ VERY SELECTIVE cases for Stem Cell Therapy when no approved available therapy is giving 
desired results after 4 to 5 years age, done as per Helsinki Protocol
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Special Education, ABA, Speech Therapy
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Cognition, behaviour, memory, speech, oro-motor 
skills, etc. are mainly controlled by Prefrontal lobe, 
Basal Ganglia, Anterior Cerebellum, Thalamus, 
lower Parietal lobe
These therapies polish up the remnant neuronal 
functions in the inflamed hypoxic brain to bring 
out the best possible improvement in a child.
However, these therapies cannot resolve / repair / 
regenerate the damaged brain areas (Penumbra) 
involved in Inflammatory HIE.
HBOT +/- SCT may, to a good extent
OT/PT, Sensory Integration Therapy
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Hyper-sensitivity to sensations like sound, 
light, touch, hyperactivity, high selective 
muscle tone, aggressive behavior, cognition & 
behavior are controlled by Frontal and 
Prefrontal lobe, Cerebellum and basal 
Ganglia.
Physical Therapies including S/I may polish up 
the remnant neuronal functions in the 
remaining normal areas in these areas of 
brain to bring out the best possible 
improvement in the child.
However, they cannot regenerate the 
inflamed HIE lesions of damaged brain for 
augmented benefits. 
HBOT +/- SCT may, to a good extent
Sensory Integration Laboratory
augments effects of OT
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Sensory Integration Therapy deserves special mention. It work to an extent we 
had not expected. The colour-changing glass fibre strands, the softly vibrating 
mattress, moving laser light show, bubble columns and soothing music helps 
calm down the child to enhance, concentration & reduce Attention Deficit 
Hyperactivity Disorder.
HBOT helps augment ALL these functions by healing the brain to a good 
extent.
Arts & Crafts and Group Activities
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These group activities enhance 
socialization, eye-hand and mental 
concentration, learning to share and 
enjoy together
These are some of our basic instincts 
and abilities, mostly fine-tuned by 
the basal ganglia, cerebellum, 
temporal lobe, and practically all 
sensory motor and emotional areas.
Inflammatory HIE in these areas 
reduces above skills. 
However, they cannot regenerate 
the inflamed HIE lesions of damaged 
brain for augmented benefits. 
HBOT +/- SCT may, to a good extent
Extramural Activities to train them to live and perform in open society
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Planning Trustees National Spokesperson inaugurating the run               Ambulance on standby
Marathon success. Our Team Felicitating the 
winners
How HBOT works: From high O2 to Cytokine 
actions 
28






You don’t need 
to know why 
the Laptop 
functions.
But you must 
know what it 
can do.
Defining Stem cells (Incl. Mesenchymal)
Called Master Cells of the body.
◦ Undifferentiated cells. Have the ability to divide and differentiate into other 200 cell types.
Stem cells distinguished from other cell types by 2 important characters 
◦ Stem cells are unspecialized cells capable of renewing themselves through cell division, sometimes after long 
periods of inactivity. 
◦ Under certain physiologic or experimental conditions, they can be induced to become tissue or organ specific 
cells with special functions, like cartilage, liver tissue, heart muscle, pancreatic tissue, nerve tissue, blood cells 
etc.
Mesenchymal cells are HLA antigen-deficient stem cells
◦ https://stemcells.nih.gov/info/basics/1.htm (last accessed 1st May 2018)
◦ https://medlineplus.gov/stemcells.html  (last accessed 1st May 2018)
◦ Human mesenchymal stem cells - current trends and future prospective; Umrao Ullah et al, Biosci Rep. 2015; 
35(2): e00191
◦ A Concise Review on the Use of Mesenchymal Stem Cells in Cell Sheet-Based Tissue Engineering with Special 
Emphasis on Bone Tissue Regeneration; Stem Cells International, Volume 2017, Article ID 2374161, 13 pages
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Dawn of a new era, using rHBOT / mHBAT
with or without stem cells
30
• Refer also to:
Anti-inflammatory and immunomodulatory mechanisms of mesenchymal stem cell transplantation in 







Totipotent (embryonic) Stem cells
CAN POTENTIALLY MAKE ANY PART, maybe even clone.
Generally not permitted due to ethical, moral, legal restrictions.
Small risk of cancer / tumor formation after 4 to 5 years
LONG TERM safety unknown though potency very good. 
GVHD (Graft versus host disease) rarely seen but what happens at micro level is unknown; 
Small stock. 
Needs Culturing and often Cell Manipulation to obtain therapeutic dose of desired specific stem cell 
line. 
◦ In culture, after about 3 passages, senescence or Genetic Micro-Array changes (mutation) may occur.
◦ Donor’s tissue antigen start to appear
◦ Their long term effect not fully studied and published.
WE LIKE TO STAY AWAY FROM IT.
31
X
Bone Marrow Stem cell (BMSC)
Bone marrow derived mononuclear cells (high % of CD34+ but low 
Mesenchymal Stem cells) with no chemical added, has stood test of 
time (> 5 decades) as reasonably effective & safe with virtually no 
risk of tumor formation.
Though adequate stock available, there remains a problem with 
senescence of the stem cells inside the recipient body, hence efficacy 
less if donor is aged > than 12 years.
Antigen matching needed if allogenic donor blood used.
No infection, no allergy, no GVHD, if used in same patient.
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BMSC Protocol for Stem Cell therapy
Requirement: > 2 - 4 million viable stem cells/ kg body wt, or more as per severity & # of sites 
Practical: one site on Bone marrow prick yields 1.2 - 2 ml Marrow, rest is oozing blood: useless. 
◦ Usually, using many pricks and twisting the needle tip, we get 60 ml of marrow
Donor age > 10 years, may have stem cells that do not last & multiply long enough in body to be 
optimally useful.
◦ Influences of age-related changes in mesenchymal stem cells on macrophages during in-vitro culture; 
Yuan Yin et al; Stem Cell Research & Therapy (2017) 8:153
Culture (passages) up to 2 yield true antigen-less copies. After 3 to 4 passages, donor HLA 
antigens start to appear. NOW, tissue matching recommended as we need a lot of stem 
cells/patient, even in a child.
Storage: kept at  -180C & transported at -80C, still 10 - 40% will degenerate. Overages needed
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Peripheral Blood Stem cells
Good for autologous (self-) use for treating acquired lesions.
Peripheral Blood has Stem Cells but the pool is very small. Collected from blood 
by apheresis (as we sometimes do for platelets).
The blood  stem cell pool may be temporarily enhanced  by injection of specific 
chemicals to make the marrow release more stem cells.
CAUTION FOR ALLOGENIC USE: Micro-array genetic changes after 3 passages on 
culture not yet studied. Most cells will be CD34+ type.
If collected at age > 12 years, the problem of senescence comes in since these 
cells do not multiply long enough inside the recipient body.
Long term safety and potency is being studied  by other researchers.
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Cord Blood Stem Cells
Autologous
If used in same patient, very safe and quite effective. BUT, small stock. Must be 
cultured to get optimum quantity. 
Long term viability issues after years of storage, even at -181C.
Cannot be used in genetic diseases in same patient as his SCs carry same defect.
Donor Pool
Pooled cord blood generally easily available. 
◦ Tissue match recommended for safety. 
◦ Proper handling, maintenance of sterility, donor history, infectious disease profile, etc. to be 
ensure stringently.
◦ Antigen matching needed if allogenic donor blood used.
◦ No infection, no allergy, no GVHD, if used in same patient.
UCBSC sources must comply with AABB, etc.
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Umbilical Cord Tissue stem cells (UCTSC)
Wharton’s Jelly, Somewhat similar to Prochymal®
The umbilical cord and placenta contains a filler tissue called 
Wharton’s Jelly comprising mostly the primitive 
Mesenchymal Stem Cells and a negligible population of 
hemopoietic Stem Cells (CD34+). Together, they offer a 
wider range of applications than either alone.
Relatively easily available after proper check-up of  viability, 
infection profile, and standardization HLA etc. analysis).
Donated UCTSC appears useful in genetic diseases
UCTSC sources must comply with AABB, etc.
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Minimal Criteria for MSC
Adherent to plastic
Surface antigens present:
◦ More than 95 % expression of CD-105, CD-73 & CD-90
◦ MSCs must NOT express (less than 2%) CD-14, CD-11b, CD-79a, CD-19, CD-34, 
CD-45 and HLA-DR)
◦ Must be capable of differentiating into various tissue types
◦ Naked cells that, till two passages of in-vitro culture, do not acquire the donor 
antigen. If obtained from umbilical cord Wharton’s Jelly, enough material 
obtained to avoid more than 2 passages.
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Int. Society for Cellular Therapy, Cytotherapy, 2006, Vol.8, No.4, Pg 3-15-317)
Mesenchymal Stem Cells (MSC)
Specific stem cells that closely resembles Embryonic Stem Cells
◦ These MSCs undergo Cell Fusion with injured resident Stem Cells.
◦ Resident stem cells in coordination with infused MSC helps to develop new 
cell types and repair injured ones. 
◦ Needed to repair / replace a tissue type; e.g.:
◦ Brain / nerve tissue in brain injury / inflammation
◦ Heart muscle tissue in AMI
◦ Pancreatic b cells in Diabetes
◦ Liver tissue in Cirrhosis; can overcome insulin resistance
◦ Lung tissue in COPD
◦ Cartilage tissue in Osteoarthrosis




Promising therapeutic effects even though the transfused cells were, 
if at all, only barely detectable in the injured organs. 
Secretes factors (Interleukins and Cytokines) that actively modulate 
debilitating local inflammatory reactions. 
Reduces apoptosis, and fibrotic tissue remodeling
Recruits resident regenerative cells to contribute towards the 
beneficial effects 
◦ A. I. Caplan and J. E. Dennis 2006; E. M. Horwitz and W. R. Prather 2003. 
◦ Treatment of stroke significantly reduces apoptosis within the 
peri-lesioned area, (J. Chen et al 2003). 
Redox Regulation by Stem Cells & HBOT
The low level of H2O2 in quiescent hematopoietic stem cells (HSCs) contributes to maintain their 
stem-ness, whereas a higher level of H2O2 within HSCs or their niche promotes differentiation, 
proliferation, migration, and survival of HSCs or stem/progenitor cells. 
Excess amounts of ROS create an inflammatory and oxidative micro-environment  cell damage 
and apoptosis of stem and progenitor cells. 
HBOT promotes progenitor cell expansion and mobilization from BM, leading to reparative 
neovascularization and tissue repair in pathophysiological states such as aging, atherosclerosis, 
heart failure, hypertension and diabetes
Understanding these molecular mechanisms will lead to the development of novel therapeutic 
strategies.
◦ Adapted from Redox regulation of stem/progenitor cells and bone marrow niche; Norifumi Urao, 
Masuko Ushio-Fukai, Dept of Pharma, Center for Lung and Vascular Biology, Center for Cardiovascular 
Research; Univ. Illinois, Chicago; Free Radic Biol Med. 2013 January ; 54: 26–39
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S.Cs regulate Cytokines just like HBOT
Stem cells down-regulate pro-inflammatory Cytokine 
after injury and reverse the cytokine effect in 2 to 3 
days of injury
◦Anti-inflammatory and immunomodulatory mechanisms 
of mesenchymal stem cell transplantation in experimental 
traumatic brain & immunomodulatory mechanisms of 
mesenchymal stem cell transplantation in experimental 
traumatic brain injury; 
◦ Run Zhang et al; J. of Neuro-inflammation; 2013: 10: 871
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Mobilisation of BM Stem Cells
42
HBOT mobilizes bone marrow derived-stem/progenitor cells by a free radical 
mediated mechanism
Post-treatment values of CD34+, CD45-dim leukocytes were always 2-fold 
greater than the pre-treatment values. 
The authors concluded that putative progenitor cell mobilization is higher with 
HBOT, and all newly mobilized cells exhibit higher concentrations of an array of 
regulatory proteins.
◦ CD34+/CD45-dim stem cell mobilization by hyperbaric oxygen – changes with oxygen dosage; 
SR Thom et al; Stem Cell Res. 2014 May; 12(3): 638–645
◦ Efficient Homing of Multipotent Adult Mesenchymal Stem Cells Depends on FROUNT-
Mediated Clustering of CCR2; Fikru Belema-Bedada at al: Cell Stem Cell, Volume 2, Issue 6, 5 
June 2008, Pages 566-575,
Composition of Adult Stem cells
CD 34+ cells are hemopoietic stem cells. A primitive subset - CD133+ cells 
differentiate into neurons.
Mesenchymal stem cells are Primitive Cell progenitors (comparable to 
embryonic stem cells). They can release Glial derived neurotrophic factor 
(GDNF).  GDNF can rescue neurons from a lack of oxygen and help stimulate the 
repair of white matter in the brain. 
CD34+ stem cells can also release Neurotrophin 3 (NT-3), Nerve Growth Factor 
(NGF) and Brain Derived Neurotrophic Factor (BDNF), which can stimulate the 
growth of new neurons. They help balance the immune system and 
autoimmune disorders, relax the artery walls which promotes improved blood 
flow. Cerebral palsy or TBI is characterized by white matter damage and is the 
best responder to adult stem cell treatments.
Biological effects of Stem Cells
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Adult MSCs are capable of dividing into one of several mesenchymal phenotypes 
such as osteoblasts, chondrocytes, myocytes, marrow stromal cells, 
tendon‐ligament fibroblasts, and adipocytes. 
These MSCs secrete a variety of cytokines and growth factors that have both 
paracrine and autocrine activities. They have bioactive factors suppress the local 
immune system, inhibit fibrosis (scar formation) and apoptosis, enhance 
angiogenesis, and stimulate mitosis and differentiation of tissue‐intrinsic 
reparative or stem cells. These effects, which are referred to as trophic effects, 
are distinct from the direct differentiation of MSCs into repair tissue. Several 
studies which tested the use of MSCs in models of infarct (injured heart), stroke 
(brain), or meniscus regeneration models examples of MSC‐mediated trophic 
effects in tissue repair.
◦ Mesenchymal stem cells as trophic mediators; A. I. Caplan et al, J. Cell. Biochem. 98: 1076-1084, 2006
Spastic paresis after perinatal brain damage in rats is 
reduced by human cord blood mononuclear cells
Therapeutic potential examined for human umbilical cord blood derived mononuclear cells 
containing multipotent stem cells to facilitate motor recovery after cerebral hypoxic-ischemic 
damage in neonatal rats. 
◦ Left carotid artery ligation followed by resuscitation was done.
◦ Histologic and immuno-histochemical analysis on postnatal d 21 revealed that neonates developed 
severe cerebral damage after the hypoxic-ischemic insult. 
After transplantation of human umbilical cord blood derived mononuclear cells, spastic paresis 
was largely alleviated, resulting in a normal walking behaviour. 
◦ This effect was accompanied by the fact that mononuclear cells had entered the brain and were 
incorporated around the lesion without obvious signs of trans differentiation. 
Their study demonstrated that intraperitoneal transplantation of human umbilical cord blood 
derived mononuclear cells in a rat model of perinatal brain damage leads to both incorporation 
of these cells in the lesioned brain area and to an alleviation of the neurologic effects of cerebral 
palsy as assessed by footprint and walking pattern analysis.
◦ Carola Meier et al, Pediatr Res 59: 244–249, 2006
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Figures in Carola Meier et al
Intraperitoneal transplantation of 
mononuclear hUCB-derived cells resulted in a 
specific homing of these cells into CNS and 
incorporation around the lesioned area
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A. Schematic representation of the distribution of human cells in the lesioned 
hemisphere. HLA-DR-positive cells (green) are detected in the area of hypoxic-ischemic 
lesion. Contralateral hemisphere devoid of human cells. 
B. HLA-DR-positive mononuclear cells (green) are located within a scaffold of GFAP-(+) 
astrocytes (red) in the area of the hypoxic-ischemic lesion. 
C. Non-lesioned parts of the brain, with absence of 
inflammatory and apoptotic events are devoid of human 
cells (absence of green fluorescence). 
D. Lesioned areas of the brain of animals that did not receive 
transplantation of human cells are devoid of 
HLA-immunostaining. Note absence of green  
(HLA-staining) within the red scaffold of GFAP-positive rat 
astrocytes.
1. Carola Meier et al, Pediatr Res 59: 244–249, 2006
Donor & Host Stem Cell Communication
Donor Stem Cells seek out Host Stem Cells 
(Chemotaxis). They adhere, not fuse, to 
each other
Donor cell shares corrective genetic codes to 
damaged host stem cells while Host stem cell 
shares information of host cell antigens
Both now normal part of same body
Khan showed it in AMI cases
◦ Oxygen and oxygenation in stem-cell therapy for myocardial infarction; 




Synergism of HBOT + Stem Cell Therapy
HBOT pre-treated Stem Cell therapy + HBOT Neuro. cases do 
better than similar groups given no pre-treatment HBOT
34 cases: M=13, F=21; Dx:  HIE (n=29), Craniocephalic trauma (n=2), Motor vehicle trauma (n=1), 
Motor vehicle Pedestrian trauma (n=2) TBI
Group 1: n-18; pre-treated with 10 HBOTs  Stem Cells  48 more HBOT sessions
Group 2: n=16; Stem Cells  48 HBOTs
Results: 
◦ Group 1 had faster & better response with the 1st signs of improvement coming after mean 2.5 weeks 
in GMFM, Speech, Attention, Function 
◦ Group 2 had similar response but after mean 4.3 weeks
“The results may well be due to the synergistic effects of  HBO followed by stem cell therapy. It is 
believed that stem cells are attracted to neural sites with neural sites with increases vascularity 
and nutrient rich environment which compensates or aids in repair of neurological damage
◦ Stem cell therapy and HBO for brain-injured children and cerebral palsy; J  L Diaz-Barbosa & F J 
Morales; Proc. 3rd Int. Symp. For CP an the Brain-Injured Child, July 2003; Fort Lauderdale, FL, USA
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Higher tissue O2 & Stem Cells in AMI
AMI  Deprivation of O2 & nutrients to heart due to blocked coronaries 
O2 required for constant energy demands of contracting heart, role in the 
regulation of heart function. However, sudden reperfusion oxygenation of the 
ischemic myocardium can be injurious.
Results from these studies demonstrate the importance of tissue oxygen in the 
application of stem-cell therapy to treat CAD. 
The transfer of gene products from injured cells may explain stem cell functional 
& phenotypic changes without the need of trans-differentiation into tissue cells. 
Transfer of gene products from stem cells may reprogram injured cells to site of 
injury 
◦ J. Int. Soc. Nephro, tissues; 2010; 78(9): 838-848
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Requirements of transplanted stem cells
51
Land unprepared. 
Cant expect a good crop
Land prepared. Expect a better crop
What is Diabetes?
52
Diabetes is a not a simplified high blood sugar disease. It is a dysfunctional disease of protein, fat 
and carbohydrate metabolism, endothelial inflammation and other complications in the CVS, 
CNS, Kidneys, NASH, Foot, DPN, etc.
◦ Bl. Sugar is just an economic test and we interpolate its results for a guess at what is happening in the 
WHOLE body.
T1DM: Direct insulin deficiency relative to body needs
T2DM: relative deficiency of insulin activity to metabolise oxydisable foods to release their 
energy for cell and body needs.
Hyperactivity of antagonistic / counteracting hormones like excessive thyroxine, steroids, 
somatostatin, catecholamine, etc.
Correct treatment mandates a correct etio-pathological diagnosis and a broad spectrum 
approach as per need.
C-Peptide
and Insulin
T1DM due to premature 
burn out of pancreatic 
b-Cells 
Cause: Auto-immunity, viral infection, genetic susceptibility, toxins
Selection: If patients have Fasting C-Peptide < 0.5, FPG > 200 mg/dl, 
PP > 300 mg/dl, often in spite of optimum available therapies
◦ One OHA that helps to an extent is metformin. I`t reduces Insulin dosage.
◦ Controlled need-based diet and lifestyle. 
◦ HBOT starts becoming helpful.
◦ Life long blood sugar monitoring at frequent intervals and Insulin injections 
are PAINFUL as only a T1DM patients knows, that, too, a child.
53
Improving C-Peptide in T1DM
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When Insulin requirements > 0.5 IU/Kg body weight along with other 
findings as mentioned above, consider SCT under Helsinki protocol, if 
the parents demand, as off-label experimental therapy.
Options
◦ Diet, life style, controlled exercise, metformin, coenzyme Q-10, 
L-Carnitine
◦ HBOT + SCT
◦ Adjuvant drugs to enhance cellular regeneration & energy output
With Regenerative Therapies, C-Peptide may creep towards or even 
reach normal, by 1 year in quite a few.




◦ HBA1c =  8.2%
◦ C-Peptide = 0.5 (N = 0.5 to 3.5)
◦ Anti-Diabetics used Insulin 41 U, 
Mid 2017
◦ Initiated oral Anti-Diabetics 
◦ HBA1c on 10/6/17 = 5.6%
◦ C-peptide on 10/8/17 = 1.5
◦ Insulin 32 U 
T2DM: relatively easy to treat with OHAs
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Metformin; Broad spectrum inulin resistance reducing agent, esp. at liver and adipose tissue. 
◦ Cardio-protective. Some role in NASH.
◦ All patients need it if tolerated
Pioglitazone: Similar to metformin as a insulin resistance reducer hypoglycemic agent.
◦ May be tried with full precaution, in patients without pre-existent heart disease, 
Sulfonylureas: Used for increasing insulin RELEASE, NOT production, if B-cells (C-Peptide) ok
Repaglinide: Release insulin by a different pathway, used in patients with irregular meal times
Alfa glucosidase inhibitors: Reduce glucose absorption from intestines, in cases who will not 
stop overeating
Gliptines: Pancreatic protector; reduce apoptosis in pancreas, for all types of T2DM
Glifozines: Enhance glucose excretion by kidneys, in cases who will not stop overeating
SCT Therapy in DM 1 & 2 from our series. 
Procedure common, but when, what, dosage, 
route: THAT is the key
SCT TO PANCREAS SCT TO LIVER
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T2DM: relatively easy to treat with OHAs
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Metformin; Broad spectrum inulin resistance reducing agent, esp. at liver and adipose tissue. 
◦ Cardio-protective. Some role in NASH.
◦ All patients need it if tolerated
Pioglitazone: Similar to metformin as a insulin resistance reducer hypoglycemic agent.
◦ May be tried with full precaution, in patients without pre-existent heart disease, 
Sulfonylureas: Used for increasing insulin RELEASE, NOT production, if B-cells (C-Peptide) ok
Repaglinide: Release insulin by a different pathway, used in patients with irregular meal times
Alfa glucosidase inhibitors: Reduce glucose absorption from intestines, in cases who will not 
stop overeating
Gliptines: Pancreatic protector; reduce apoptosis in pancreas, for all types of T2DM





Our Ultimate aim: 
Help as a Physician should
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